help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Published ahead of print on September 13, 2007, doi:10.1164/rccm.200703-489OC
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Online Supplement
Right arrow All Versions of this Article:
200703-489OCv1
176/12/1215    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Parr, D. G.
Right arrow Articles by Stockley, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Parr, D. G.
Right arrow Articles by Stockley, R. A.
American Journal of Respiratory and Critical Care Medicine Vol 176. pp. 1215-1221, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200703-489OC

Original Article

Prevalence and Impact of Bronchiectasis in {alpha}1-Antitrypsin Deficiency

David G. Parr1,2, Peter G. Guest3, John H. Reynolds4, Lee J. Dowson5 and Robert A. Stockley2

1 Department of Respiratory Medicine, University Hospitals of Coventry and Warwickshire, Coventry; 2 Lung Investigation Unit and 3 Department of Radiology, University Hospital, Birmingham; 4 Department of Radiology, Birmingham Heartlands Hospital, Birmingham; and 5 Department of Respiratory Medicine, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom

Correspondence and requests for reprints should be addressed to David G. Parr, M.D., Department of Respiratory Medicine, University Hospitals of Coventry and Warwickshire, Coventry CV2 2DX, UK. E-mail: david.parr{at}uhcw.nhs.uk

Rationale: {alpha}1-Antitrypsin (AAT) deficiency is associated with increased risk of chronic obstructive pulmonary disease (COPD), in particular emphysema, but airway disease is less well described.

Objectives: To assess the prevalence of airways disease in subjects with AAT deficiency and to identify the relationship between radiological airway abnormalities and clinical phenotype.

Methods: We characterized the computed tomographic phenotype of 74 subjects (PiZ), using visual scoring of airway disease and densitometric assessment of emphysema. Computed tomographic measurements were related to physiology, health status (St. George's Respiratory Questionnaire), and emphysema severity, and the relative impact of airway disease and emphysema severity on health status and airflow obstruction was compared by stepwise regression.

Measurements and Main Results: Bronchiectatic changes were seen in 70 subjects, and a subgroup with a bronchiectasis-predominant phenotype was identified. Clinically significant bronchiectasis (radiologic bronchiectasis in 4 or more bronchopulmonary segments together with symptoms of regular sputum production) occurred in 20 subjects (27%). AAT-deficient index cases had higher airway disease scores (P < 0.05), more severe emphysema (P < 0.001), and greater impairment of physiology (P < 0.001) and health status (P < 0.05) than nonindex cases. Airway disease scores correlated with health status, and bronchial wall thickening correlated with FEV1. Regression analysis indicated that emphysema severity had the strongest associations for health status (r = 0.505, P < 0.001) and FEV1 (r = 0.699, P < 0.001), but the addition of airway disease score improved the regression models (r = 0.596, P = 0.002 and r = 0.783, P < 0.001, respectively).

Conclusions: Emphysema is the predominant component of COPD in AAT deficiency, but the prevalence and impact of airway disease are greater than currently recognized. Consequently, future therapeutic strategies in AAT deficiency should also target this component of COPD.

Key Words: chronic obstructive pulmonary disease • emphysema • bronchiectasis • computed tomography • {alpha}1-antitryspin deficiency


AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject
Bronchiectasis is recognized in {alpha}1-antitrypsin (AAT) deficiency but data are limited concerning the frequency and type of bronchiectasis, as well as the clinical and physiologic manifestations.

What This Study Adds to the Field
Emphysema is the predominant component of COPD in AAT deficiency, but the prevalence and impact of airway disease are greater than currently recognized. Consequently, future therapeutic strategies in AAT deficiency should also target this component of COPD.

 



This article has been cited by other articles:


Home page
 NEJMHome page
E. K. Silverman and R. A. Sandhaus
Alpha1-Antitrypsin Deficiency
N. Engl. J. Med., June 25, 2009; 360(26): 2749 - 2757.
[Full Text] [PDF]

Home page
 ChestHome page
A. E. O'Donnell
Bronchiectasis
Chest, October 1, 2008; 134(4): 815 - 823.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. D. Chan and M. D. Iseman
Significance of Bronchiectasis in Patients with {alpha}1-Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 208 - 208.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. G. Parr, P. G. Guest, J. H. Reynolds, L. J. Dowson, and R. A. Stockley
Significance of Bronchiectasis in Patients with {alpha}1-Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., July 15, 2008; 178(2): 208 - 209.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society 		  Membership Renewal